175 related articles for article (PubMed ID: 9866424)
1. [Cytarabine-induced pericarditis].
Yamada T; Tsurumi H; Hara T; Sawada M; Oyama M; Moriwaki H
Rinsho Ketsueki; 1998 Nov; 39(11):1115-20. PubMed ID: 9866424
[TBL] [Abstract][Full Text] [Related]
2. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
3. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
5. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Koyama S; Itou S; Shibata A
Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
[TBL] [Abstract][Full Text] [Related]
6. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
8. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
9. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
Kumagawa M; Suzuki K; Nagano M; Takamatsu Y; Suzumiya J; Tamura K
Rinsho Ketsueki; 2003 Jun; 44(6):404-6. PubMed ID: 12884821
[TBL] [Abstract][Full Text] [Related]
10. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
[TBL] [Abstract][Full Text] [Related]
11. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
12. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
; ; . PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
